SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 103 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $3,851,000 | -7.5% | 4,000,000 | +14.3% | 0.21% | +18.4% |
| Q1 2022 | $4,165,000 | -57.4% | 3,500,000 | +16.7% | 0.17% | -34.3% |
| Q4 2021 | $9,780,000 | +9.4% | 3,000,000 | +50.0% | 0.26% | +32.5% |
| Q3 2021 | $8,940,000 | -3.5% | 2,000,000 | +17.6% | 0.20% | +6.4% |
| Q2 2021 | $9,265,000 | +20.8% | 1,700,000 | +65.9% | 0.19% | +39.3% |
| Q1 2021 | $7,667,000 | -5.8% | 1,025,000 | +36.7% | 0.14% | -22.9% |
| Q4 2020 | $8,138,000 | +97.8% | 750,000 | +61.1% | 0.18% | +75.0% |
| Q3 2020 | $4,115,000 | -21.2% | 465,500 | -5.0% | 0.10% | -31.5% |
| Q2 2020 | $5,223,000 | +74.0% | 490,000 | -3.2% | 0.15% | +15.0% |
| Q1 2020 | $3,001,000 | – | 506,138 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |